• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Elevance Health Inc.

    3/28/25 5:06:57 PM ET
    $ELV
    Medical Specialities
    Health Care
    Get the next $ELV alert in real time by email
    DEFA14A 1 a2025defa14aproxynotice.htm DEFA14A a2025defa14aproxynotice
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☑ Definitive Additional Materials ☐ Soliciting Material under §240.14a-12 Elevance Health, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) PAYMENT OF FILING FEE (CHECK ALL BOXES THAT APPLY): ☑ No fee required ☐ Fee paid previously with preliminary materials ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11


     
    Step 1: Go to www.envisionreports.com/elv Step 2: Click on Cast Your Vote or Request Materials. Step 3: Follow the instructions on the screen to log in. www.envisionreports.com/elv Online Go to www.envisionreports.com/elv or scan the QR code — login details are located in the shaded bar below. Shareholder Meeting Notice 0438HE Important Notice Regarding the Availability of Proxy Materials for the Elevance Health Shareholder Meeting to be Held on May 14, 2025 Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual shareholders’ meeting are available on the internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and instructions for participating in the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The Notice of Annual Meeting of Shareholders, Proxy Statement and 2024 Annual Report on Form 10-K are available at: Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before May 4, 2025 to facilitate timely delivery. 2 N O T Easy Online Access — View your proxy materials and vote. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. The Sample Company Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares. If you hold Elevance Health Plan or Puerto Rico Retirement Plan Shares, votes submitted must be received by 11:59 p.m., Eastern Time, on May 9, 2025. MMMMMMMMMMMM M M M M M M M M M 0 0 0 0 0 1 MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 ENDORSEMENT_LINE______________ SACKPACK_____________ 1234 5678 9012 345 C 1234567890 C O Y MMMMMMM


     
    Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.envisionreports.com/elv. Click Cast Your Vote or Request Materials. — Phone – Call us free of charge at 1-866-641-4276. — Email – Send an email to [email protected] with “Proxy Materials Elevance Health” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by May 4, 2025. Elevance Health’s Annual Meeting of Shareholders will be held on May 14, 2025 at 8:00 a.m. Eastern Time in a virtual format only, via live audio webcast at https://meetnow.global/M7G4Q92. To log in to the audio webcast as a shareholder, you must have the information that is printed in the shaded bar located on the reverse side of this form. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommends a vote FOR each of the nominees listed in Proposal 1 and FOR Proposals 2 and 3. 1. Election of Directors: 01 - Susan D. DeVore 02 - Bahija Jallal 03 - Ryan M. Schneider 2. Advisory vote to approve the compensation of our named executive officers. 3. To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2025. The Board of Directors recommends a vote AGAINST Proposal 4. 4. Shareholder proposal requesting report on the effectiveness of Diversity, Equity and Inclusion efforts. In their discretion, the persons named as proxies are authorized to vote on any other business that may properly come before the 2025 Annual Meeting of Shareholders or any adjournment or postponement thereof. Shareholder Meeting Notice The Annual Meeting of Shareholders will be held in a virtual format only, via live audio webcast. Shareholders who participate in the virtual Annual Meeting of Shareholders may vote, submit questions and view the list of our shareholders of record during the Annual Meeting of Shareholders. Meeting Date and Time: May 14, 2025 at 8:00 a.m. Eastern Time Meeting Access: https://meetnow.global/M7G4Q92 The audio webcast is compatible with all common web browsers and may be viewed on mobile devices. Online access to the audio webcast will open 15 minutes prior to the start of the Annual Meeting of Shareholders to allow time to log in and test your device’s audio system. We encourage you to access the meeting in advance of the designated start time. To log in to the webcast as a shareholder of record or an associate shareholder, visit the meeting access link, click “Join Meeting Now” and provide your control number from the reverse side of this notice. You will be asked to accept Computershare’s Terms and Conditions. If you do not have internet access and want to listen to the Annual Meeting of Shareholders, please contact Elevance Health Shareholder Services at [email protected] or call (800) 985-0999 by May 12, 2025, for alternative access instructions. PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. If you wish to vote through the live webcast during the virtual Annual Meeting of Shareholders, please follow the directions above to log in to the webcast as a shareholder.


     
    Get the next $ELV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELV

    DatePrice TargetRatingAnalyst
    4/15/2025$529.00Outperform → Neutral
    Robert W. Baird
    3/17/2025$450.00Hold → Buy
    Argus
    1/22/2025$520.00 → $440.00Overweight → Equal-Weight
    Stephens
    10/18/2024Buy → Hold
    Argus
    7/18/2024$646.00 → $530.00Buy → Neutral
    BofA Securities
    6/24/2024$643.00Overweight
    Morgan Stanley
    5/30/2024$649.00Outperform
    Robert W. Baird
    3/6/2024$584.00Overweight
    Barclays
    More analyst ratings

    $ELV
    Financials

    Live finance-specific insights

    See more
    • Elevance Health Reports First Quarter 2025 Results

      1Q 2025 operating revenue of $48.8 billion, up 15.4% from 1Q 2024 1Q 2025 adjusted operating gain1 of $3.3 billion, up 4.1% from 1Q 2024 1Q 2025 diluted EPS2 of $9.61; adjusted diluted EPS1 of $11.97 Reaffirm FY 2025 adjusted diluted EPS1 of $34.15 to $34.85 Returned $1.3 billion of capital to shareholders in 1Q 2025 Elevance Health, Inc. (NYSE:ELV) reported first quarter 2025 results. "At Elevance Health, our purpose—to improve the health of humanity—drives everything we do. In the first quarter, we made measurable progress reimagining the healthcare experience with personalized support, real-time digital solutions, and a whole-health model that improves outcomes and reduces co

      4/22/25 6:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health to Hold Conference Call and Webcast to Discuss First Quarter 2025 Results on April 22, 2025

      Elevance Health (NYSE:ELV) will release first quarter 2025 financial results on April 22, 2025, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 – Access Code - 3972058 (Domestic) 312-470-0178 – Access Code - 3972058 (International) 800-396-1242 – No Access Code (Domestic Replay) 203-369-3272 – No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on April 22, 2025, until the end of the day on May 22, 2025. The call will als

      3/31/25 4:05:00 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Outlook

      4Q 2024 operating revenue of $45.0 billion; FY 2024 of $175.2 billion 4Q 2024 diluted EPS1 of $1.81; adjusted diluted EPS2 of $3.84 FY 2024 diluted EPS1 of $25.68; adjusted diluted EPS2 of $33.04 Projected FY 2025 GAAP diluted EPS1 to be in the range of $30.40 to $31.10 Projected FY 2025 adjusted diluted EPS2 to be in the range of $34.15 to $34.85 Quarterly dividend increased by 5% to $1.71 per share Elevance Health, Inc. (NYSE:ELV) reported fourth quarter and full year 2024 results. "As part of our commitment to elevating whole health and advancing health beyond healthcare, we deliver value to the members and care providers we serve by ensuring simple, affordable, and

      1/23/25 6:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Elevance Health downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Elevance Health from Outperform to Neutral and set a new price target of $529.00

      4/15/25 9:24:40 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health upgraded by Argus with a new price target

      Argus upgraded Elevance Health from Hold to Buy and set a new price target of $450.00

      3/17/25 8:22:06 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health downgraded by Stephens with a new price target

      Stephens downgraded Elevance Health from Overweight to Equal-Weight and set a new price target of $440.00 from $520.00 previously

      1/22/25 7:37:04 AM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Elevance Health Reports First Quarter 2025 Results

      1Q 2025 operating revenue of $48.8 billion, up 15.4% from 1Q 2024 1Q 2025 adjusted operating gain1 of $3.3 billion, up 4.1% from 1Q 2024 1Q 2025 diluted EPS2 of $9.61; adjusted diluted EPS1 of $11.97 Reaffirm FY 2025 adjusted diluted EPS1 of $34.15 to $34.85 Returned $1.3 billion of capital to shareholders in 1Q 2025 Elevance Health, Inc. (NYSE:ELV) reported first quarter 2025 results. "At Elevance Health, our purpose—to improve the health of humanity—drives everything we do. In the first quarter, we made measurable progress reimagining the healthcare experience with personalized support, real-time digital solutions, and a whole-health model that improves outcomes and reduces co

      4/22/25 6:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health to Hold Conference Call and Webcast to Discuss First Quarter 2025 Results on April 22, 2025

      Elevance Health (NYSE:ELV) will release first quarter 2025 financial results on April 22, 2025, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 – Access Code - 3972058 (Domestic) 312-470-0178 – Access Code - 3972058 (International) 800-396-1242 – No Access Code (Domestic Replay) 203-369-3272 – No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on April 22, 2025, until the end of the day on May 22, 2025. The call will als

      3/31/25 4:05:00 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Outlook

      4Q 2024 operating revenue of $45.0 billion; FY 2024 of $175.2 billion 4Q 2024 diluted EPS1 of $1.81; adjusted diluted EPS2 of $3.84 FY 2024 diluted EPS1 of $25.68; adjusted diluted EPS2 of $33.04 Projected FY 2025 GAAP diluted EPS1 to be in the range of $30.40 to $31.10 Projected FY 2025 adjusted diluted EPS2 to be in the range of $34.15 to $34.85 Quarterly dividend increased by 5% to $1.71 per share Elevance Health, Inc. (NYSE:ELV) reported fourth quarter and full year 2024 results. "As part of our commitment to elevating whole health and advancing health beyond healthcare, we deliver value to the members and care providers we serve by ensuring simple, affordable, and

      1/23/25 6:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Strable-Soethout Deanna D was granted 601 shares, increasing direct ownership by 58% to 1,646 units (SEC Form 4)

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      5/16/25 4:19:25 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Director Schneider Ryan M. was granted 601 shares, increasing direct ownership by 10% to 6,600 units (SEC Form 4)

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      5/16/25 4:18:55 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Director Peru Ramiro G was granted 601 shares, increasing direct ownership by 7% to 9,345 units (SEC Form 4)

      4 - Elevance Health, Inc. (0001156039) (Issuer)

      5/16/25 4:18:24 PM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Elevance Health Inc.

      SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)

      11/14/24 1:22:35 PM ET
      $ELV
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Elevance Health Inc.

      SC 13G - Elevance Health, Inc. (0001156039) (Subject)

      2/14/24 10:02:59 AM ET
      $ELV
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Elevance Health Inc.

      SC 13G - Elevance Health, Inc. (0001156039) (Subject)

      2/14/23 12:37:59 PM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    SEC Filings

    See more
    • Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Elevance Health, Inc. (0001156039) (Filer)

      5/28/25 6:31:33 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Elevance Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Elevance Health, Inc. (0001156039) (Filer)

      5/14/25 5:27:34 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Elevance Health Inc.

      SCHEDULE 13G/A - Elevance Health, Inc. (0001156039) (Subject)

      5/7/25 10:07:38 AM ET
      $ELV
      Medical Specialities
      Health Care

    $ELV
    Leadership Updates

    Live Leadership Updates

    See more
    • Elevance Health Appoints Nathan Rich Vice President, Investor Relations

      Elevance Health (NYSE:ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company's growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company's executive leadership team and will report directly to Mark Kaye, Executive Vice President and Chief Financial Officer. Mr. Rich succeeds Stephen Tanal, who now serves as Chief Financial Officer for Elevance Health's Government Health Benefits business. "Nate brings nearly two decades of expe

      11/4/24 9:00:00 AM ET
      $ELV
      Medical Specialities
      Health Care
    • Former Deputy Commissioner of New York State Department of Health Joins Sheppard Mullin

      Nationally Recognized Healthcare Policy Leader Adam Herbst Strengthens the Firm's Regulatory Capabilities for Clients Across the Post-Acute, Aging and Long-Term Care Sectors Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Adam S. Herbst has joined the firm as a healthcare partner in New York. Most recently, Herbst served as the New York State Department of Health's Deputy Commissioner for Aging and Long Term Care. He is the ninth healthcare partner to join the firm in 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241030758975/en/Adam Herbst (Photo: Business Wire) In joining Sheppard Mullin's industry-l

      10/30/24 12:55:00 PM ET
      $ELV
      Medical Specialities
      Health Care
    • Performant Financial Corporation Announces the Appointment of Dr. Shantanu Agrawal to Its Board of Directors

      Performant Financial Corporation (NASDAQ:PFMT) (Performant), primarily operating as Performant Healthcare Solutions, a leading provider of technology-enabled payment integrity, eligibility, and related analytics services, is proud to announce the appointment of Dr. Shantanu Agrawal, M.D. to its Board of Directors. Dr. Agrawal brings a wealth of expertise and experience in healthcare policy and payment integrity. As Chief Health Officer at Elevance Health (NYSE:ELV), Dr. Agrawal oversees the whole health strategy, including medical policy and clinical quality, as well as the community health strategy and Elevance Health Foundation. Prior to Elevance Health, Dr. Agrawal held numerous execut

      3/6/24 4:30:00 PM ET
      $ELV
      $PFMT
      Medical Specialities
      Health Care
      Other Consumer Services
      Consumer Discretionary